CRISPR/Cas9-mediated β-globin gene knockout in rabbits recapitulates human β-thalassemia
- PMID: 33639162
- PMCID: PMC8024976
- DOI: 10.1016/j.jbc.2021.100464
CRISPR/Cas9-mediated β-globin gene knockout in rabbits recapitulates human β-thalassemia
Abstract
β-thalassemia, an autosomal recessive blood disorder that reduces the production of hemoglobin, is majorly caused by the point mutation of the HBB gene resulting in reduced or absent β-globin chains of the hemoglobin tetramer. Animal models recapitulating both the phenotype and genotype of human disease are valuable in the exploration of pathophysiology and for in vivo evaluation of novel therapeutic treatments. The docile temperament, short vital cycles, and low cost of rabbits make them an attractive animal model. However, β-thalassemia rabbit models are currently unavailable. Here, using CRISPR/Cas9-mediated genome editing, we point mutated the rabbit β-globin gene HBB2 with high efficiency and generated a β-thalassemia rabbit model. Hematological and histological analyses demonstrated that the genotypic mosaic F0 displayed a mild phenotype of anemia, and the heterozygous F1 exhibited typical characteristics of β-thalassemia. Whole-blood transcriptome analysis revealed that the gene expression was altered in HBB2-targeted when compared with WT rabbits. And the highly expressed genes in HBB2-targeted rabbits were enriched in lipid and iron metabolism, innate immunity, and hematopoietic processes. In conclusion, using CRISPR-mediated HBB2 knockout, we have created a β-thalassemia rabbit model that accurately recapitulates the human disease phenotype. We believe this tool will be valuable in advancing the investigation of pathogenesis and novel therapeutic targets of β-thalassemia and associated complications.
Keywords: CRISPR/Cas; animal model; gene therapy; genetic disease; hemoglobin; rabbit; β-thalassemia.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.
Figures





Similar articles
-
CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.Hum Genet. 2023 Dec;142(12):1677-1703. doi: 10.1007/s00439-023-02610-9. Epub 2023 Oct 25. Hum Genet. 2023. PMID: 37878144 Review.
-
The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.Sci Rep. 2016 Sep 1;6:32463. doi: 10.1038/srep32463. Sci Rep. 2016. PMID: 27581487 Free PMC article.
-
Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.Sci Rep. 2015 Jul 9;5:12065. doi: 10.1038/srep12065. Sci Rep. 2015. PMID: 26156589 Free PMC article.
-
Generation of an in vitro model of β-thalassemia using the CRISPR/Cas9 genome editing system.J Cell Biochem. 2020 Feb;121(2):1420-1430. doi: 10.1002/jcb.29377. Epub 2019 Oct 9. J Cell Biochem. 2020. PMID: 31596028
-
Gene Therapy and Genome Editing.Hematol Oncol Clin North Am. 2018 Apr;32(2):329-342. doi: 10.1016/j.hoc.2017.11.007. Epub 2018 Jan 9. Hematol Oncol Clin North Am. 2018. PMID: 29458735 Review.
Cited by
-
CRISPR technology in human diseases.MedComm (2020). 2024 Jul 29;5(8):e672. doi: 10.1002/mco2.672. eCollection 2024 Aug. MedComm (2020). 2024. PMID: 39081515 Free PMC article. Review.
-
CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.Hum Genet. 2023 Dec;142(12):1677-1703. doi: 10.1007/s00439-023-02610-9. Epub 2023 Oct 25. Hum Genet. 2023. PMID: 37878144 Review.
-
Spatial and Temporal Expression Characteristics of the HBB Gene Family in Six Different Pig Breeds.Genes (Basel). 2022 Oct 9;13(10):1822. doi: 10.3390/genes13101822. Genes (Basel). 2022. PMID: 36292707 Free PMC article.
-
Genome-edited rabbits: Unleashing the potential of a promising experimental animal model across diverse diseases.Zool Res. 2024 Mar 18;45(2):253-262. doi: 10.24272/j.issn.2095-8137.2023.201. Zool Res. 2024. PMID: 38287906 Free PMC article. Review.
References
-
- Cohen A.R., Galanello R., Pennell D.J., Cunningham M.J., Vichinsky E. Thalassemia. Hematology Am. Soc. Hematol. Educ. Program. 2004:14–34. - PubMed
-
- Cao A., Galanello R. Beta-thalassemia. Genet. Med. 2010;12:61–76. - PubMed
-
- Farmakis D., Giakoumis A., Polymeropoulos E., Aessopos A. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med. Sci. Monit. 2003;9:RA19–RA22. - PubMed
-
- Shamshirsaz A.A., Bekheirnia M.R., Kamgar M., Pourzahedgilani N., Bouzari N., Habibzadeh M., Hashemi R., Shamshirsaz A.A., Aghakhani S., Homayoun H., Larijani B. Metabolic and endocrinologic complications in beta-thalassemia major: A multicenter study in Tehran. BMC Endocr. Disord. 2003;3:4. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials